Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons

Clinical Infectious Diseases

Volumn 41, Issue 7, 2005, Pages 1045-1048

  Overton, Edgar Turner ^a   Sungkanuparph, Somnuek ^a   Powderly, William G ^c   Seyfried, Warren ^a   Groger, Richard K ^a   Aberg, Judith A ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; VIRUS RNA;

ADULT; ANTIBODY RESPONSE; ARTICLE; COHORT ANALYSIS; DRUG RESPONSE; FEMALE; HEPATITIS B; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; VACCINATION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RNA, VIRAL; VIRAL LOAD;

EID: 25444498267     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/433180     Document Type: Article

References (24)

1. Homann C, Krogsgaard K, Pedersen C, Andersson P, Nielsen JO. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr 1991; 4:416-20.
2. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003; 23:125-36.
3. Bodsworth N, Cooper D, Donovan B. The influence of HIV-1 infection on the development of hepatitis B virus carrier state. J Infect Dis 1991; 163:1138-40.
4. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B in homosexual men: effects on the natural history of infection. AIDS 1997; 11:597-606.
5. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360:1921-6.
6. Keet IP, van Doornum G, Safary A, Coutinho RA. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS 1992; 6:509-10.
7. Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV infected individuals. AIDS 1994; 8:558-9.
8. Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV infected persons. J Clin Gastroenterol 1992; 14:27-30.
9. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B vaccination strategies using cost effectiveness analysis. Ann Intern Med 1993; 118:298-306.
10. Van Herck K, Van Damme P, Thoelen S, Meheus A. Long-term persistence of antiHBs after vaccination with a recombinant DBA yeast-derived hepatitis B vaccine: 8 year results. Vaccine 1998; 16:1933-5.
11. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002: recommendations of the US Public Health Service and the Infectious Diseases Society of America. US Public Health Service, Infectious Diseases Society of America. Ann Intern Med 2002; 137:435-78.
12. Roberts IM, Bernard CC, Vyas GN, Mackay IR. T-cell dependence of immune response to hepatitis B surface antigen in mice. Nature 1975; 254:606-7.
13. Chang TW, Cells E, Miller RW, Zurawski VR Jr, Kung PC. In vitro response to HBsAg of peripheral blood lymphocytes from vaccine recipients of hepatitis B vaccine. Hepatology 1984; 4:824-9.
14. Iwarson S, Wahl M, Ruttimann E, Snoy P, Seto B, Gerety RJ. Successful postexposure vaccination against hepatitis B in chimpanzees. J Med Virol 1988; 25:433-9.
15. Desombere I, Gijbels Y, Verwulgen A, Leroux-Roels G. Characterization of the T cell recognition of hepatitis B surface antigen by good and poor responders to hepatitis B vaccines. Clin Exp Immunol 2000; 122: 390-9.
16. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21:265-304.
17. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000; 14:11-21.
18. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long lasting recovery of CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-6.
19. Andersson J, Fehniger TE, Patterson BK, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998; 12:F123-9.
20. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissue to antiretroviral therapy of HIV-1 infection. Science 1997; 276:960-4.
21. + T cell homeostasis and unction in advanced HIV disease. Science 1997; 277:112-6.
22. Pontesilli O, Kerkhof-Garde SR, Notermans DW, et al. Functional T cell reconstitution and HIV-1 specific cell-mediated immunity during highly active antiretroviral therapy (HAART). J Infect Dis 1999; 180: 76-86.
23. Tedaldi EM, Baker RK, Moorman AC, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004; 38:1478-84.
24. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002; 51(RR-6):1-78. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ rr5106a1.htm.